Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Cmc topic
No spam. Unsubscribe anytime.
Draft guidance details what CMC data sponsors can leverage for gene‑therapy development
Summary
OTP presenters listed CMC examples that may be leveraged — analytical methods and validation, lot release specs, stability data, comparability and process characterization — while warning product differences may require product‑specific verification.
Stella Lee, presenting OTP's CMC examples, said the draft guidance "provides examples of the type of CMC information that may be leveraged, including analytical methods and method qualification, validation data, lot release specification, stability data, comparability data, and process characterization and validation data." The agency noted this list is not exhaustive and sponsors should discuss leveraging options with OTP early.
Lee walked through specific scenarios: verification may be needed when assay performance could be affected by different guide RNA sequences, stability data from representative clinical lots may support early‑phase trials or commercial shelf life when manufacturing and formulation are comparable, and PPQ data from an established product can inform PPQ study design for similar platform variants.
